MUMBAI, September 20, 2012 /PRNewswire/ --

Glenmark Generics Inc., USA, the United States subsidiary of Glenmark Generics Limited, announced today that the United States Food and Drug Administration (U.S. FDA) has granted tentative approval for Rizatriptan Benzoate tablets, its generic version of Merck's Maxalt® tablets.

According to IMS Health for the 12 month period ending June 2012, Rizatriptan Benzoate immediate release tablets achieved sales of USD 315 million.

Glenmark's current portfolio consists of 81 products authorized for distribution in the U.S. marketplace and 41 ANDA's pending approval with the U.S. FDA.

About Glenmark Generics Limited:

Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America and developing an EU presence It primarily sells its FDF products in the United States ("US") and the European Union ("EU"), as well as its oncology FDF products in South America. The Company supplies APIs to customers in approximately 63 countries, including the US, various countries in the EU, South America and India.

Primary Media Contact: Corporate Communications, connect@glenmark-generics.com, 91-22-40189999